Background: Cancer-specific autoantibodies found in serum of cancer patients have
| INTRODUCTION
Gliomas are the most common malignant primary brain tumors, which represent approximately 30% of all central nervous system (CNS) tumors and 80% of all malignant brain tumors. Gliobastoma is the most common malignant glioma (World Health Organization [WHO] grade IV) with an incidence rate of 3.2 per 100 000 population. 1, 2 O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein, which removes the cytotoxic O6-methylguanine (O6-MG) DNA lesions generated by temozolomide (TMZ), an oral methylating agent used in the treatment of primary CNS tumors and melanoma. A high MGMT expression in cells is the predominant mechanism underlying tumor resistance to alkylating agents. [3] [4] [5] [6] Currently, it has been shown that MGMT methylation or protein expression can be used as useful predictive biomarkers during temozolomide chemotherapy. [7] [8] [9] [10] MGMT methylation status testing by methylation-specific PCR, immunohistochemistry (IHC) or pyrosequencing has been established as a routine molecular pathological technique for patients with glioma. Yet, these methods have several limitations, including a high false-positive rate, difficulty in gaining access to human samples and substantial costs. 11, 12 Therefore, there is an urgent need for more effective, noninvasive method for the screening of MGMT. Autoantibodies against tumor-associated antigens (TAAs) are attractive targets for the development of noninvasive serological tests, which have shown to be useful for predicting high risk of recurrence and/or treatment response. [13] [14] [15] [16] [17] In the present study, we conducted a peptide microarray to examine whether humoral immunity participated in the immune process to elicit autoantibodies against MGMT in gliomas, as well as to investigate whether MGMT autoantibodies could be used as biomarkers for monitoring the recurrence and prediction of treatment response of glioma. 
| MATERIALS AND METHODS

| Collection of serum samples
| Peptide microarray
Preparation of peptides microarray and serum screening were according to previously described approach. 21, 22 Briefly, synthetic peptides were spotted onto the activated iPDMS membranes to form a 9 × 9 microarrays using a contact printer Smart 48 (Capitalbio, Beijing, China). Human-IgG (H-IgG, DGCS-Bio, Beijing, China) was used as positive control in each subarray at the concentration of 50 μg/mL, while printing buffer served as negative control. In each subarray there were four positive controls printed with H-IgG at the concentration of 50 μg/mL, and one negative control printed with printing buffer (Figure 1 and Table S1 ).
| Serological screening
A total of 2-μL serum samples were diluted 1:100 with a sample dilution buffer and incubated at 200 μL per well 
| Statistical analysis
Each microarray image was processed using GenePix Pro 6.0 software to calculate the median chemiluminescence intensity of each dot, which was converted to signal-tonoise ratio (SNR) by subtracting the background intensity averaged from the intensity from eight blank dots, and calculated using the following formula: (signal intensity-background intensity)/(background intensity). The digitized image from each microarray was then imported into R for further analysis. The R package "p-heatmap" was used for cluster analysis. The cut-off values of each peptide autoantibodies were determined as the SNR that yields maximum difference of positive response rate between glioma and healthy normal group. The differences between groups were analyzed by Fisher's exact test; Bonferroni corrections were performed for multiple comparisons. Samples with SNR ≥ each peptide cut-off value were considered as seropositive reaction. The coverage of a peptide to a set of serum samples was defined as the ratio of the seropositive serum numbers to the whole set numbers. Correlation among variables was assessed using the nonparametric Spearman coefficient. A P < 0.05 was considered statistically significant. Recurrence-free survival (RFS) was defined as the interval from the date of surgery to the date of glioma recurrence as a time-to-event end point. Survival curves were estimated by the Kaplan-Meier method and compared using the logrank test. Hazard ratios with 95% confidence intervals were calculated after univariate and multivariate analysis using the multiple Cox regression analysis with forward selection. All statistical tests were two-sided, and P < 0.05 indicated a significant difference. These analyses were performed using the statistical software with SPSS (version 21, SPSS Company, Chicago, IL).
| RESULTS
| Primary analysis of candidate sequences
The peptides microarrays were incubated with the sera from 378 subjects (67 glioma patients and 311 healthy donors) were used for the serological screening of MGMT autoantibody peptides. The bound IgG was detected by HRP-conjugated secondary antibody. Each serum sample was incubated with two peptide microarrays. The results of microarray screening between glioma group and healthy group are shown in Figure S1 . Cluster analysis of the two groups was carried out, revealing that peptides showed significantly higher responses in glioma than healthy individuals (Figure 2 ). The cut-off value of each peptide autoantibody and maximum difference of positive response rate between glioma and healthy normal group are shown in Table 3 .
| Correlation of MGMT autoantibody and its Protein Expression
MGMT autoantibody and its protein expression were performed on same series of glioma samples. Samples with SNR ≥ each peptide (MGMT-02, MGMT-04, MGMT-07, MGMT-10, MGMT-18) cut-off value were considered as seropositive reaction. The results showed significant positive correlation between MGMT autoantibody seropositive reaction and its protein expression with a Spearman Correlation Coefficient of r = 0.553 and P < 0.001 values (Table 4) .
| The changing of preoperative, postoperative, and recurrence MGMT autoantibodies
We used the collected 52 serum samples of glioma 30 days postoperatively, and 11 serum samples of recurrent gliomas detected the five-peptide responses necessary for investigation of the changing regularity of serum MGMT autoantibodies, which are shown in Figure 3 . We observed that the autoantibody coverage of peptide in five peptides was lower at 30 days postoperatively than preoperatively. In 10 patients whose MGMT autoantibodies were positive preoperatively, the sera autoantibody levels were also examined 30 days after surgery revealing that decreased levels of five peptide autoantibodies (Figure 4 ).
When the tumor reoccurs, we found that the anti-MGMT-02, anti-MGMT-07, and anti-MGMT-10 peptide autoantibodies coverage of peptide increased. However, only anti-MGMT-02 peptide autoantibodies had a higher coverage of peptide than the preoperative when tumor recurrence developed. We also followed up 10 glioma patients sera (5 seropositive patients and 5 seronegative patients of preoperative) autoantibody levels during postoperative 30 days and the tumor recurrence to validate the changing of anti-MGMT-02 peptide autoantibody level ( Figure 5 ). Among 5 seropositive patients, the anti-MGMT-02 autoantibody peptide level decreased 30 days after surgery; 4 out of the 5 seropositive patients became seronegative, 5 patients with anti-MGMT-02 peptide autoantibodies reached preoperative levels again when tumor recurrence developed ( Figure 5A ). In 5 seronegative patients, anti-MGMT-02 peptide autoantibody level remained seronegative; not only 30 days postoperatively but also when tumor recurred ( Figure 5B ). Monitoring of anti-MGMT-02 peptide autoantibody levels was useful for identifying patients with glioma recurrence from preoperative seropositive patients.
| MGMT autoantibody status and level in association with Treatment Response in entire glioma population
We evaluated the clinical impact of MGMT autoantibody status and the level of the prediction of recurrence-free survival (RFS) in 56 glioma patients with various grade (WHO grade II, n = 16; WHO grade III, n = 25; WHO grade IV, n = 15). All glioma patients received operative intervention (mean resection rate was 95%), and chemoradiotherapy and chemotherapy with temozolomide according to the NCCN regimen. [23] [24] [25] The major factors such as sex, age, Ki-67, and glioma grade were investigated（low-grade glioma (WHO grade II) and high-grade glioma (WHO grade III-IV). The status of MGMT peptide autoantibodies was divided into two groups according to the cut-off value of each peptide, negative group (SNR value < cut-off value) and positive group (SNR value > cut-off value). Univariate and multivariate analysis showed that preoperative anti-MGMT-02 peptide autoantibodies status was an independent risk factor for RFS; the negative group showed significantly better recurrence-free survival than the positive group (P < 0.05; Figure 6A ,B), suggesting the possibility of using the preoperative anti-MGMT-02 peptide autoantibodies as a predictive marker of recurrence. Patient' age, gender, Ki-67, and glioma grade were not significant variables (Table 5) . Perioperative monitoring of anti-MGMT-02 peptide autoantibody levels was useful for identifying patients with glioma at poor prognosis and a high risk of tumor recurrence and poor prognosis. 
| DISCUSSION
Monitoring treatment response and recurrence, prompt treatment regimen can be used to reduce mortality and improve prognosis. Unfortunately, this can be challenging because of the low specificity and sensitivity of the less invasive methodologies currently available, and because refined diagnosis requires resection or biopsy to obtain tumor tissue for genetic or IHC biomarkers. Yet, repeated sampling of tumor tissue is not always appropriate because it is an invasive approach, which affects the clinical diagnosis and design of individualized treatment ultimately compromising the treatment effect. 26 Our results showed that the autoantibodies to MGMT peptides can be detectable. Furthermore, we identified five highly responsive peptides in the glioma sera. The mechanism underlying anti-MGMT peptides autoantibody production still remains unclear; however, it might be associated with the MGMT protein overexpression. Because tumor development is often accompanied with the overexpression of tumor-associated antigens (TAAs) which may elicit immune responses resulting in the production of anti-TAA autoantibodies, even when antigen expression is minimal, serum autoantibodies can be detected. 27 Our present study also showed MGMT autoantibody and its protein expression exhibited a significant correlation (Spearman's r = 0.553, P < 0.001). We validated its value in patients at different time points learning that the coverage ratio of all five autoantibody peptides had decreased 30 days after operation compared to levels before surgery; however, only MGMT-02 peptide reached preoperative levels when tumor recurrence developed. When the tumor was resected, the antigen in the body was removed, causing the immune response to be reduced, so the expression of peptides was decreased. Therefore, these cancer-associated autoantibodies might be considered as reporters from the immune system, that can identify the antigenic changes of cellular proteins involved in the transformation process. 28, 29 When the glioma recurred, the tumor cells secreted antigens, and the peptides increased. In our study, we also found that 
F I G U R E 6
Recurrence-free survival curves of patients according to autoantibodies to MGMT-02 peptide levels after combined radiochemotherapy with temozolomide. Negative group (SNR value <5.5), positive group (SNR value ≥5.5). In the univariate analysis (A) and multivariate analysis (B), MGMT-02 peptide was significantly correlated to the recurrence-free survival of patients. P < 0.05 was considered statistically significant peptides were increased before recurrence. Therefore, monitoring anti-MGMT-02 peptides autoantibody could be valuable for the recurrence of glioma. We also investigated the relationships between preoperative MGMT autoantibody and treatment response in highgrade glioma patients who underwent surgery following radiochemotherapy with temozolomide. We found that the seropositivity of MGMT-02 peptide autoantibody in glioma patient serum was associated with shorter recurrence-free survival compared with the seronegative patients. The preoperative anti-MGMT-02 peptide autoantibody levels were significantly correlated with the effect of the postoperative for chemotherapy with temozolomide, further indicating its clinical utility for monitoring the response to therapy.
T A B L E 5 Multivariable survival analysis for RFS
Variables
There are several limitations in the present study. First, it is a retrospective study conducted at one single institute, where only 67 glioma patients were included in our filter set, which might cause the limitation of our findings. Second, a large multicenter study investigating the validity of the cutoff value of each peptide autoantibody, the association between the preoperative MGMT autoantibody level and RFS would enhance the findings of the current study and provide crucial information on the utility of MGMT autoantibody levels as a prognostic marker for glioma recurrence and treatment response.
